Outcomes of endoscopic submucosal dissection for high-risk colorectal colitis-associated neoplasia in inflammatory bowel disease
- PMID: 39848273
- DOI: 10.1055/a-2524-3553
Outcomes of endoscopic submucosal dissection for high-risk colorectal colitis-associated neoplasia in inflammatory bowel disease
Abstract
Background: Patients with inflammatory bowel disease (IBD) have an increased risk of colorectal cancer. High-risk colorectal colitis-associated neoplasia (HR-CAN) can be difficult to treat using traditional endoscopic resection methods. This study evaluated the outcomes of endoscopic submucosal dissection (ESD) in patients with IBD and HR-CANs.
Methods: This retrospective multicenter study consecutively included patients with IBD who were referred to expert Italian endoscopy centers for ESD or hybrid ESD (hESD) of HR-CANs. The main outcomes were rates of en bloc, R0, and curative resections, adverse events, local recurrence, metachronous lesions, and post-resection surgery. Kaplan-Meier method was used to analyze survival rates. Risk factors associated with the main outcomes were investigated by univariable analysis.
Results: 91 patients with colonic IBD (disease duration 15.3 [SD 8.7] years, 82.4 % with ulcerative colitis) with 96 HR-CANs (mean size 34.8 [SD 16.2] mm, 53.1 % high grade dysplasia/adenocarcinoma) were included. ESD and hESD were performed in 82.3 % and 17.7 %, respectively. En bloc, R0, and curative resections were achieved in 95.8 % (95 %CI 89.6-98.8), 85.4 % (95 %CI 76.7-91.7), and 83.3 % (95 %CI 74.3-90.1). Adverse events occurred in 12.5 % (95 %CI 6.6-20.8), which were all conservatively managed. After a mean follow-up of 23.4 (SD 16.1) months, local recurrence and metachronous lesions each occurred in 3.1 %. Post-resection surgery was required in 11.5 %.
Conclusions: ESD of HR-CANs showed favorable outcomes on the medium- and long-term course in patients with IBD.
Thieme. All rights reserved.
Conflict of interest statement
R. Maselli is a consultant for ERBE, Fujifilm, 3DMatrix, and Boston Scientific. F. Barbaro is a consultant for Olympus. G. Andrisani is a consultant for ERBE and Fujifilm. C. Spada is a consultant for Medtronic, Olympus, Pentax, Norgine and AnX Robotics. C. Hassan is a consultant for Fujifilm, Medtronic, and Olympus. A. Repici is a consultant for Medtronic, ERBE, Fujifilm, and Olympus. The remaining authors declare that they have no conflict of interest.
Publication types
MeSH terms
LinkOut - more resources
Medical
Research Materials
Miscellaneous